1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril has been researched along with Lymphoma, Non-Hodgkin in 1 studies
*Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baars, JW; Beijnen, JH; Hoefnagel, CA; Huitema, AD; Maessen, HJ; Tran, L | 1 |
1 other study(ies) available for 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Equipment Design; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Mice; Protein Binding; Quality Control; Radiation Protection; Radioimmunotherapy; Radiopharmaceuticals; Rituximab; Urea | 2009 |